Not FDA-Approved — Research Use Only
This compound is for in-vitro laboratory research only. It is not approved by the FDA for any therapeutic, diagnostic, or clinical use and is not for human consumption of any kind. See the full disclaimer.
Retatrutide
Triple agonist peptide. GLP-1/GIP/Glucagon receptor activity. 10mg research vial.
Size
Research Use Only
All products are intended solely for laboratory research and are not for human consumption of any kind. By purchasing, the buyer agrees to use these products in compliance with all applicable laws. See the disclaimer and terms.
COA available upon request
Analytical Data
Look up batch COAMethod
Reversed-phase HPLC
Purity Specification
99.0% (batch-specific value on COA)
Each batch must meet a minimum purity of 98% as determined by reversed-phase HPLC before release. The exact measured value for your batch is recorded on the batch-specific Certificate of Analysis.
Values describe the batch specification only. See the COA disclaimer for scope and limitations.
Specifications
| Name | Retatrutide |
| CAS Number | 2381089-83-2 |
| Molecular Weight | 4625.27 g/mol |
| Purity | 99.0% |
| Vial Size | 10mg |
| Appearance | White to off-white lyophilized powder |
| Storage | -20°C, protect from light and moisture |
Related Products
Tirzepatide
Dual GIP/GLP-1 receptor agonist. Investigational metabolic peptide. 10mg research vial.
Semaglutide
GLP-1 receptor agonist peptide. 31 amino acid modified sequence. 10mg research vial.
Retatrutide
Triple agonist peptide. GLP-1/GIP/Glucagon receptor activity. 20mg research vial.
Tirzepatide
Dual GIP/GLP-1 receptor agonist. Investigational metabolic peptide. 20mg research vial.